Clinical Trial

Neoadjuvant Intense Endocrine Therapy for High Risk and Locally Advanced Prostate Cancer

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This is a prospective, multicenter, multi-arm, non-randomized, open-label clinical trial to evaluate the efficacy and safety of neoadjuvant intense endocrine therapy for high-risk or locally advanced prostate cancer.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2022-06-04; most recent amendment 2022-08-12.
Status change: Not Yet Recruiting → Recruiting 2022-07-13
Trial Details
NCT Number NCT05406999
Lead Sponsor The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Conditions Neoadjuvant Therapy, High Risk Prostate Cancer, Locally Advanced Prostate Cancer, Intense Endocrine Therapy
Enrollment 900 participants
Start Date 2020-02-01
Primary Completion 2026-12-31 (estimated)
Study Completion 2030-06-30 (estimated)
Updated on ClinicalTrials.gov 2022-08-16